Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation

References

• Hindricks G, Potpara T, Dagres N, et al. ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498. 2020.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi: 10.7326/0003-4819-146-12-200706190-00007
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi: 10.1016/S0140-6736(13)62343-0
   PubMed Web of Science ®Google Scholar
• Escobar C, Martí-Almor J, Pérez Cabeza A, et al. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed). 2019;72(4):305–316. doi: 10.1016/j.recesp.2018.02.023
   PubMed Web of Science ®Google Scholar
• Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022 Jan 25;145(4):242–255. doi: 10.1161/CIRCULATIONAHA.121.056355
   PubMed Web of Science ®Google Scholar
• Zhou X, SC D Jr. Evidence for inflammation as a driver of atrial fibrillation. Front Cardiovasc Med. 2020 Apr 29;7:62. doi: 10.3389/fcvm.2020.00062
   PubMed Web of Science ®Google Scholar
• Youn JY, Zhang J, Zhang Y, et al. Oxidative stress in atrial fibrillation: an emerging role of NADPH oxidase. J Mol Cell Cardiol. 2013 Sep;62:72–79.
   PubMed Web of Science ®Google Scholar
• Corban MT, Toya T, Ahmad A, et al. Atrial fibrillation and endothelial dysfunction: a potential link? Mayo Clin Proc. 2021 Jun;96(6):1609–1621. doi: 10.1016/j.mayocp.2020.11.005
   PubMed Web of Science ®Google Scholar
• Bassand JP, Accetta G, Camm AJ, et al. GARFIELD-AF investigators. Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016 Oct 7;37(38):2882–2889. doi: 10.1093/eurheartj/ehw233
   PubMed Web of Science ®Google Scholar
• Barrios V, Almendro-Delia M, Facila L, et al. Rivaroxaban: searching the integral vascular protection. Expert Rev Clin Pharmacol. 2018 Jul;11(7):719–728. doi: 10.1080/17512433.2018.1495559
   PubMed Web of Science ®Google Scholar
• Olesen JB, Gislason GH, Torp-Pedersen C, et al. Atrial fibrillation and vascular disease–a bad combination. Clin Cardiol. 2012 Jan;1(Suppl 1):15–20. 35 Suppl. doi: 10.1002/clc.20955
   Google Scholar
• Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther. 2013 Feb;11(2):129–141. doi: 10.1586/erc.12.172
   PubMedGoogle Scholar
• Xarelto. Summary of product characteristics. Accessed on 3 Aug 2023. Available from at: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_en.pdf
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi: 10.1056/NEJMoa1009638
   PubMed Web of Science ®Google Scholar
• Funatsu T, Yamashita A, Kaku S, et al. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models. Thromb Haemost. 2012;108(5):896–902. doi: 10.1160/TH12-04-0267
   PubMed Web of Science ®Google Scholar
• Hara T, Fukuda D, Tanaka K, et al. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice. Atherosclerosis. 2015;242(2):639–646. doi: 10.1016/j.atherosclerosis.2015.03.023
   PubMed Web of Science ®Google Scholar
• Wu TC, Chan JS, Lee CY, et al. Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice. Cardiovasc Diabetol. 2015;14(1):81. doi: 10.1186/s12933-015-0243-y
   PubMedGoogle Scholar
• Moñux G, Zamorano-León JJ, Marqués P, et al. Fxa inhibition by rivaroxaban modifies mechanisms associated with the pathogenesis of human abdominal aortic aneurysms. Br J Clin Pharmacol. 2017;83(12):2661–2670. doi: 10.1111/bcp.13383
   PubMed Web of Science ®Google Scholar
• Namba S, Yamaoka-Tojo M, Kakizaki R, et al. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels. 2017;32(8):977–982. doi: 10.1007/s00380-017-0950-2
   PubMed Web of Science ®Google Scholar
• Álvarez E, Paradela-Dobarro B, Raposeiras-Roubín S, et al. Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium. Br J Clin Pharmacol. 2018;84(2):280–291. doi: 10.1111/bcp.13440
   PubMed Web of Science ®Google Scholar
• Bode MF, Auriemma AC, Grover SP, et al. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction. Thromb Res. 2018;167:128–134. doi: 10.1016/j.thromres.2018.05.015
   PubMed Web of Science ®Google Scholar
• Liu J, Nishida M, Inui H, et al. Rivaroxaban suppresses the progression of ischemic cardiomyopathy in a murine model of diet-induced myocardial infarction. J Atheroscler Thromb. 2019;26(10):915–930. doi: 10.5551/jat.48405
   PubMed Web of Science ®Google Scholar
• Petzold T, Thienel M, Dannenberg L, et al. Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res. 2020;126(4):486–500. doi: 10.1161/CIRCRESAHA.119.315099
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Kaikita K, Ishii M, et al. Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice. Circ Rep. 2020;2(3):158–166. doi: 10.1253/circrep.CR-19-0117
   PubMedGoogle Scholar
• Pistrosch F, Matschke JB, Schipp D, et al. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. Diabetologia. 2021;64(12):2701–2712. doi: 10.1007/s00125-021-05562-9
   PubMed Web of Science ®Google Scholar
• Bunch TJ. Atrial fibrillation and dementia. Circulation. 2020 Aug 18;142(7):618–620. doi: 10.1161/CIRCULATIONAHA.120.045866
   PubMed Web of Science ®Google Scholar
• Zenger B, Rizzi S, Steinberg BA, et al. This is Your Brain, and this is Your Brain on atrial fibrillation: the roles of cardiac malperfusion events and vascular dysfunction in cognitive impairment. Arrhythm Electrophysiol Rev. 2023;12:e01. doi: 10.15420/aer.2022.29
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–322. doi: 10.1016/S1474-4422(12)70042-X
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37(14):1145–1153. doi: 10.1093/eurheartj/ehv466
   PubMed Web of Science ®Google Scholar
• Marín F, Fernández MS, Barón-Esquivias G, et al. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban. J Comp Eff Res. 2023;12(3):e220049. doi: 10.57264/cer-2022-0049
   PubMed Web of Science ®Google Scholar
• Talmor-Barkan Y, Yacovzada NS, Rossman H, et al. Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial. Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):26–37. doi: 10.1093/ehjcvp/pvac063
   PubMedGoogle Scholar
• Fernández MS, Marín F, Rafols C, et al. The EMIR study investigators: thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res. 2021 May;10(7):583–593. doi: 10.2217/cer-2020-0286
   PubMed Web of Science ®Google Scholar
• Kim D, Yang PS, Jang E, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. EP Europace. 2021 Feb 5;23(2):184–195. doi: 10.1093/europace/euaa192
   PubMed Web of Science ®Google Scholar
• Lee ZX, Ang E, Lim XT, et al. Association of risk of dementia with direct oral anticoagulants versus warfarin use in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2021 Jan 1;77(1):22–31. doi: 10.1097/FJC.0000000000000925
   PubMed Web of Science ®Google Scholar
• Bian Z, Liu X, Feng T, et al. Protective effect of rivaroxaban against amyloid pathology and neuroinflammation through inhibiting PAR-1 and PAR-2 in alzheimer’s disease mice. J Alzheimers Dis. 2022;86(1):111–123. doi: 10.3233/JAD-215318
   PubMed Web of Science ®Google Scholar
• Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107–114. doi: 10.1001/jamainternmed.2013.11912
   PubMed Web of Science ®Google Scholar
• Abolbashari M. Atherosclerosis and atrial fibrillation: double trouble. Curr Cardiol Rep. 2022 Feb;24(2):67–73. doi: 10.1007/s11886-021-01625-w
   PubMed Web of Science ®Google Scholar
• Oancea AF, Jigoranu RA, Morariu PC, et al. Atrial fibrillation and chronic coronary ischemia: a challenging vicious circle. Life (Basel). 2023;13(6):1370. doi: 10.3390/life13061370
   PubMed Web of Science ®Google Scholar
• Batta A, Hatwal J, Batta A, et al. Atrial fibrillation and coronary artery disease: an integrative review focusing on therapeutic implications of this relationship. World J Cardiol. 2023;15(5):229–243. doi: 10.4330/wjc.v15.i5.229
   PubMed Web of Science ®Google Scholar
• Steensig K, Olesen KKW, Thim T, et al. Should the presence or Extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the Western Denmark Heart registry. Thromb Haemost. 2018;118(12):2162–2170. doi: 10.1055/s-0038-1675401
   PubMed Web of Science ®Google Scholar
• Miao B, Hernandez AV, Roman YM, et al. Four-year incidence of major adverse cardiovascular events in patients with atherosclerosis and atrial fibrillation. Clin Cardiol. 2020 May;43(5):524–531. doi: 10.1002/clc.23344
   PubMed Web of Science ®Google Scholar
• Lee CJ, Gerds TA, Carlson N, et al. Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2018 Jul 3;72(1):17–26. doi: 10.1016/j.jacc.2018.04.036
   PubMed Web of Science ®Google Scholar
• Chai-Adisaksopha C, Hillis C, Isayama T, et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015 Nov;13(11):2012–2020. doi: 10.1111/jth.13139
   PubMed Web of Science ®Google Scholar
• Grajek S, Kałużna-Oleksy M, Siller-Matula JM, et al. Non-vitamin K antagonist oral anticoagulants and risk of myocardial infarction in patients with atrial fibrillation with or without percutaneous coronary interventions: a meta-analysis. J Pers Med. 2021 Oct 9;11(10):1013. doi: 10.3390/jpm11101013
   PubMed Web of Science ®Google Scholar
• Kupó P, Szakács Z, Solymár M, et al. Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis. Angiology. 2020 Jan;71(1):27–37. doi: 10.1177/0003319719874255
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Stevens SR, White HD, et al. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J. 2014 Jan;35(4):233–241. doi: 10.1093/eurheartj/eht428
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sharma A, Uchino K, et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis. 2013 Dec;24(8):628–635. doi: 10.1097/MCA.0000000000000031
   PubMed Web of Science ®Google Scholar
• De Luca L. Low-dose rivaroxaban: can cardiovascular events be reduced? Eur Heart J Suppl. 25(Suppl C): PMID: 37125297; PMCID: PMC10132608:C20–C26. 2023 Apr 26. doi: 10.1093/eurheartjsupp/suad034
   PubMedGoogle Scholar
• Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017 Oct 5;377(14):1319–1330. doi: 10.1056/NEJMoa1709118
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423–2434. doi: 10.1056/NEJMoa1611594
   PubMed Web of Science ®Google Scholar
• Zeymer U, Toelg R, Wienbergen H, et al. Rivaroxaban in patients with atrial fibrillation who underwent percutaneous coronary intervention in clinical practice. Am J Cardiol. 2023 Feb 15;189:31–37. doi: 10.1016/j.amjcard.2022.11.009
   PubMed Web of Science ®Google Scholar
• Yasuda S, Kaikita K, Akao M, et al. AFIRE investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019 Sep 19;381(12):1103–1113. doi: 10.1056/NEJMoa1904143
   PubMed Web of Science ®Google Scholar
• Zhu J, Tan X, Zhou JZ. Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2021 Aug;44(8):1050–1057. doi: 10.1002/clc.23678
   PubMed Web of Science ®Google Scholar
• Anandasundaram B, Lane DA, Apostolakis S, et al. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost. 2013 May;11(5):975–987. doi: 10.1111/jth.12177
   PubMed Web of Science ®Google Scholar
• Vitalis A, Shantsila A, Proietti M, et al. Peripheral arterial disease in patients with atrial fibrillation: the AFFIRM study. Am J Med. 2021 Apr;134(4):514–518. doi: 10.1016/j.amjmed.2020.08.026
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229. doi: 10.1016/S0140-6736(17)32409-1
   PubMed Web of Science ®Google Scholar
• Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018 May 22;71(20):2306–2315. doi: 10.1016/j.jacc.2018.03.008
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020 May 21;382(21):1994–2004. doi: 10.1056/NEJMoa2000052
   PubMed Web of Science ®Google Scholar
• Hao Y, Han W, Mou D, et al. Efficacy and safety of rivaroxaban therapy for patients with peripheral artery disease: a systematic review and meta-analysis. Vasc Endovascular Surg. 2021 Oct;55(7):712–720. doi: 10.1177/15385744211012916
   PubMed Web of Science ®Google Scholar
• Aune D, Feng T, Schlesinger S, et al. Diabetes mellitus, blood glucose and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. J Diabetes Complications. 2018;32(5):501–511. doi: 10.1016/j.jdiacomp.2018.02.004
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi: 10.1056/NEJMoa0905561
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi: 10.1056/NEJMoa1107039
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–2104. doi: 10.1056/NEJMoa1310907
   PubMed Web of Science ®Google Scholar
• Xu J, Sun Y, Gong D, et al. Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: a meta-analysis. Front Endocrinol. 2022 Aug 1;13:921159. doi: 10.3389/fendo.2022.921159
   PubMed Web of Science ®Google Scholar
• Leopoulou M, Theofilis P, Kordalis A, et al. Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment. World J Diabetes. 2023;14(5):512–527. doi: 10.4239/wjd.v14.i5.512
   PubMed Web of Science ®Google Scholar
• Alwafi H, Alotaibi B, Naser AY, et al. The safety and efficacy of the use of oral anticoagulant medications in patients with diabetes mellitus: a systematic review. Saudi Pharm J. 2021;29(12):1374–1382. doi: 10.1016/j.jsps.2021.11.001
   PubMed Web of Science ®Google Scholar
• Bansilal S, Bloomgarden Z, Halperin JL, et al. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF trial). Am Heart J. 2015 Oct;170(4):675–682.e8. doi: 10.1016/j.ahj.2015.07.006
   PubMed Web of Science ®Google Scholar
• Hua Y, Sun JY, Su Y, et al. The safety and efficacy of rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021 Jan;21(1):51–61. doi: 10.1007/s40256-020-00407-z
   PubMed Web of Science ®Google Scholar
• Weir MR, Chen YW, He J, et al. Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. J Diabetes Complications. 2021 Nov;35(11):108029. doi: 10.1016/j.jdiacomp.2021.108029
   PubMed Web of Science ®Google Scholar
• Berger JS, Ashton V, Laliberté F, et al. Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with diabetes in a US population. Adv Ther. 2023 Mar;40(3):1224–1241. doi: 10.1007/s12325-022-02422-9
   PubMed Web of Science ®Google Scholar
• Baker WL, Beyer-Westendorf J, Bunz TJ, et al. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes. Diab Obes Metab. 2019 Sep;21(9):2107–2114. doi: 10.1111/dom.13787
   PubMed Web of Science ®Google Scholar
• Costa OS, O’Donnell B, Vardar B, et al. Kidney, limb and ophthalmic complications, and death in patients with nonvalvular atrial fibrillation and type 2 diabetes prescribed rivaroxaban or warfarin: an electronic health record analysis. Curr Med Res Opin. 2021;37(9):1493–1500. doi: 10.1080/03007995.2021.1947217
   PubMed Web of Science ®Google Scholar
• Brambatti M, Darius H, Oldgren J, et al. Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: results from the RE-LY trial. Int J Cardiol. 2015 Oct 1;196:127–131. doi: 10.1016/j.ijcard.2015.05.141
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Lewis BS, Lopes RD, et al. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):86–94. doi: 10.1093/ehjcvp/pvu024
   PubMed Web of Science ®Google Scholar
• Plitt A, Ruff CT, Goudev A, et al. Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. Int J Cardiol. 2020;304:185–191. doi: 10.1016/j.ijcard.2020.01.009
   PubMed Web of Science ®Google Scholar
• Coleman CI, Costa OS, Brescia CW, et al. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Cardiovasc Diabetol. 2021 Feb 26;20(1):52. doi: 10.1186/s12933-021-01250-5
   PubMed Web of Science ®Google Scholar
• Barrios V, Górriz JL. Atrial fibrillation and chronic kidney disease: focus on rivaroxaban. J Comp Eff Res. 2015 Nov;4(6):651–664. doi: 10.2217/cer.15.44
   PubMed Web of Science ®Google Scholar
• Gadde S, Kalluru R, Cherukuri SP, et al. Atrial fibrillation in chronic kidney disease: an overview. Cureus. 2022;14(8):e27753. doi: 10.7759/cureus.27753
   PubMed Web of Science ®Google Scholar
• Ding WY, Gupta D, Wong CF, et al. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021;117(4):1046–1059. doi: 10.1093/cvr/cvaa258
   PubMed Web of Science ®Google Scholar
• Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016 Sep 6;354:i4482. doi: 10.1136/bmj.i4482
   PubMedGoogle Scholar
• Airy M, Schold JD, Jolly SE, et al. Cause-specific mortality in patients with chronic kidney disease and atrial fibrillation. Am J Nephrol. 2018;48(1):36–45. doi: 10.1159/000491023
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Renal insufficiency should be included in stroke risk scores. Kidney Int. 2013 Jun;83(6):1204–1205. doi: 10.1038/ki.2013.35
   PubMed Web of Science ®Google Scholar
• Lobos-Bejarano JM, Castellanos Rodríguez A, Barrios V, et al. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists. Int J Clin Pract. 2017 Sep;71(9):e12974. doi: 10.1111/ijcp.12974
   Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–2394. doi: 10.1093/eurheartj/ehr342
   PubMed Web of Science ®Google Scholar
• Di Lullo L, Tripepi G, Ronco C, et al. Safety and effectiveness of rivaroxaban and warfarin in moderate-to-advanced CKD: real world data. J Nephrol. 2018 Oct;31(5):751–756. doi: 10.1007/s40620-018-0501-7
   PubMed Web of Science ®Google Scholar
• Weir MR, Haskell L, Berger JS, et al. Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. Clin Nephrol. 2018 May;89(5):314–329. doi: 10.5414/CN109281
   PubMed Web of Science ®Google Scholar
• Rivera-Caravaca JM, Anguita Sanchez M, Sanmartín Fernández M, et al. Adverse clinical outcomes and associated predictors in rivaroxaban-treated atrial fibrillation patients with renal impairment. Am J Cardiol. 2023 Jul 22;203:122–127. doi: 10.1016/j.amjcard.2023.06.105
   PubMed Web of Science ®Google Scholar
• Lee WC, Lee PW, Wu PJ, et al. The impact on renal function after long-term use of anticoagulants in atrial fibrillation patients. Thromb J. 2021 Dec 11;19(1):98. doi: 10.1186/s12959-021-00351-1
   PubMed Web of Science ®Google Scholar
• Zhang C, Gu ZC, Ding Z, et al. Decreased risk of renal impairment in atrial fibrillation patients receiving non-vitamin K antagonist oral anticoagulants: a pooled analysis of randomized controlled trials and real-world studies. Thromb Res. 2019 Feb;174:16–23.
   PubMed Web of Science ®Google Scholar
• Pastori D, Ettorre E, Lip GYH, et al. Association of different oral anticoagulants use with renal function worsening in patients with atrial fibrillation: a multicentre cohort study. Br J Clin Pharmacol. 2020 Dec;86(12):2455–2463. doi: 10.1111/bcp.14350
   PubMed Web of Science ®Google Scholar
• Yao X, Tangri N, Gersh BJ, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017 Nov 28;70(21):2621–2632. doi: 10.1016/j.jacc.2017.09.1087
   PubMed Web of Science ®Google Scholar
• Kreutz RH. Rivaroxaban associates with reduced risk of adverse kidney outcomes in comparison to vitamin K antagonist treatment in a prospective real-world study in patients with non-valvular atrial fibrillation and advanced chronic kidney disease. J Am Coll Cardiol. 2023 Mar;81(8_Supplement):108. doi: 10.1016/S0735-1097(23)00552-1
   Web of Science ®Google Scholar
• López-Gálvez R, Rivera-Caravaca JM, Anguita Sánchez M, et al. Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788
   PubMed Web of Science ®Google Scholar
• Özbudak E, Eraldemir FC, Arıkan AA, et al. An evaluation of rivaroxaban and clopidogrel in a rat lower extremity ischemia-reperfusion model: an experimental study. Turk Gogus Kalp Damar Cerrahisi Derg. 2019;27(4):513–520. doi: 10.5606/tgkdc.dergisi.2019.18061
   PubMed Web of Science ®Google Scholar
• Samiei F, Sajjadi H, Jamshidzadeh A, et al. Contrasting role of concentration in rivaroxaban induced toxicity and oxidative stress in isolated kidney mitochondria. Drug Res (Stuttg). 2019;69(10):523–527. doi:10.1055/a-1001-2154
   PubMed Web of Science ®Google Scholar
• Al-Harbi NO, Imam F, Alharbi MM, et al. Role of rivaroxaban in sunitinib-induced renal injuries via inhibition of oxidative stress-induced apoptosis and inflammation through the tissue nacrosis factor-α induced nuclear factor-κappa B signaling pathway in rats. J Thromb Thrombolysis. 2020;50(2):361–370. doi: 10.1007/s11239-020-02123-6
   PubMed Web of Science ®Google Scholar
• Durmaz S, Kurtoğlu T, Rahman ÖF, et al. Direct oral anticoagulant agents attenuate temporary aortic occlusion-induced renal oxidative and inflammatory responses in rats. Turk Gogus Kalp Damar Cerrahisi Derg. 2022;30(2):184–191. doi: 10.5606/tgkdc.dergisi.2022.22831
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Caluwé R, Der Meersch H V, et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021;32(6):1474–1483. doi: 10.1681/ASN.2020111566
   PubMed Web of Science ®Google Scholar
• Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781–2789. doi: 10.1093/eurheartj/ehr113
   PubMed Web of Science ®Google Scholar
• Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708. doi: 10.1056/NEJMoa1105819
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. RE-DUAL PCI Steering Committee and investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524. doi: 10.1056/NEJMoa1708454
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. AUGUSTUS investigators. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524. doi: 10.1056/NEJMoa1817083
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343. doi: 10.1016/S0140-6736(19)31872-0
   PubMed Web of Science ®Google Scholar